Literature DB >> 31677719

Exploring the dietary protein intake and skeletal muscle during first-line anti-neoplastic treatment in patients with non-small cell lung cancer.

Randi Tobberup1, Henrik H Rasmussen2, Mette Holst2, Nikolaj A Jensen3, Ursula G Falkmer4, Martin Bøgsted5, Agnieszka M Delekta6, Andreas Carus4.   

Abstract

BACKGROUND: Loss of skeletal muscle mass is the corner stone of cancer cachexia, but no effective therapies are yet identified. The optimal protein quantity and pattern to support muscle mass maintenance in cancer patients is unknown. The aim of the current exploratory study was to observe the pattern and quantity of dietary protein intake as well as the prevalence of muscle wasting in patients with inoperable non-small cell lung cancer (NSCLC) undergoing primary anti-neoplastic treatment. The secondary aim was to assess the potential contributory factors associated with maintenance of muscle mass.
METHOD: A longitudinal observational study was conducted in patients with NSCLC undergoing first line of anti-neoplastic treatment. Nutrient intake was assessed by repeated 24-h recalls and skeletal muscle by routine thoraco-abdominal CT scans at baseline and after three cycles of treatment. Descriptive analyses, paired samples t-test, binomial logistic and linear regression analyses were performed.
RESULTS: Out of 186 consecutively screened patients, 62 were included and 52 patients were available for analysis. Protein intake increased from baseline to follow up, but were lower in muscle wasters (1.0 g/kg/d) than in muscle maintainers (1.4 g/kg/d). The majority of the meals contributed less than 20 g of protein and less than 10% of the meals contributed at least 40 g of protein. Significant loss of skeletal muscle area was observed in 26 out of 52 patients. A higher protein intake (OR 18.7, p = 0.01), energy intake (OR 1.1, p = 0.04) and stable body weight (OR 1.2, p = 0.03) were associated with muscle maintenance in the univariate regression, whereas age, sex, cachexia, tumour stage, treatment adherence and response did not. In the multivariate regression, a trend was seen for protein intake (OR 35.2, p = 0.08) and body weight (OR 1.2, p = 0.06).
CONCLUSION: Muscle wasting occurred frequently and early during primary anti-neoplastic treatment. Protein intake seems important for maintaining skeletal muscle. Validated dietary methods in cancer patients must be identified and the optimal protein quantity and intake pattern to support muscle maintenance should be explored in future trials.
Copyright © 2019 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cachexia; Malignancy; NSCLC; Protein pattern; Protein pulse feeding; Sarcopenia

Mesh:

Substances:

Year:  2019        PMID: 31677719     DOI: 10.1016/j.clnesp.2019.08.006

Source DB:  PubMed          Journal:  Clin Nutr ESPEN        ISSN: 2405-4577


  3 in total

Review 1.  Impact and Treatment of Sarcopenia in Patients Undergoing Radiotherapy: A Multidisciplinary, AMSTAR-2 Compliant Review of Systematic Reviews and Metanalyses.

Authors:  Federica Medici; Alberto Bazzocchi; Milly Buwenge; Alice Zamagni; Gabriella Macchia; Francesco Deodato; Savino Cilla; Pierandrea De Iaco; Anna Myriam Perrone; Lidia Strigari; Stefania Rizzo; Alessio G Morganti
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 2.  Protein intake and muscle mass maintenance in patients with cancer types with high prevalence of sarcopenia: a systematic review.

Authors:  Carolina Capitão; Diana Coutinho; Pedro Miguel Neves; Manuel Luís Capelas; Nuno M Pimenta; Teresa Santos; Antti Mäkitie; Paula Ravasco
Journal:  Support Care Cancer       Date:  2021-10-25       Impact factor: 3.603

3.  Changes in body composition in patients with malignant pleural mesothelioma and the relationship with activity levels and dietary intake.

Authors:  Emily Jeffery; Y C Gary Lee; Robert U Newton; Philippa Lyons-Wall; Joanne McVeigh; Deirdre B Fitzgerald; Leon Straker; Carolyn J Peddle-McIntyre
Journal:  Eur J Clin Nutr       Date:  2022-01-17       Impact factor: 4.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.